Respiratory

Central sleep apnea: distinguishing features and treatment

Clinical Overview and When to Suspect Central Sleep Apnea

— Stable HFrEF patient (LVEF ≤45%) with daytime fatigue, paroxysmal nocturnal dyspnea, or refractory symptoms despite GDMT

— Patient on chronic opioids (especially methadone or long-acting morphine ≥200 MME/day) reporting witnessed apneas

— Post-stroke patient with disordered breathing in the first weeks of recovery

— High-altitude sojourner (>2500 m) with periodic breathing and insomnia

— Atrial fibrillation that recurs despite rhythm control, especially with EF reduction

— Treatment-emergent CSA: patient started on CPAP for OSA who develops new central events ("complex sleep apnea")

— CSA prevalence in chronic HFrEF: 25–40%; in stable opioid users: up to 30%

— Male predominance, age >65, AF, hypocapnia awake (PaCO₂ <38) all raise pre-test probability

Board pearl: A patient with HFrEF, witnessed apneas, and a crescendo-decrescendo breathing pattern with apneas at the nadir has Cheyne-Stokes respiration — a form of CSA, not OSA. Order polysomnography, optimize GDMT first, and do NOT start adaptive servo-ventilation if LVEF ≤45% (SERVE-HF mortality signal).

Definition: Central sleep apnea (CSA) is characterized by repetitive cessation or reduction of airflow during sleep due to loss of ventilatory drive — absent thoracoabdominal effort — rather than upper airway collapse seen in OSA.

Diagnostic threshold (AASM): Central apnea-hypopnea index (CAHI) ≥5/hr with >50% of events being central, plus symptoms (sleepiness, insomnia, awakening short of breath, witnessed apneas) or an associated comorbidity.

When to suspect on Step 3:

Epidemiology pearls:

Pathophysiology snapshot: High loop gain → unstable chemoreflex → overshoot ventilation → PaCO₂ drops below apneic threshold → central pause → CO₂ rises → arousal → cycle repeats (Cheyne-Stokes pattern in HF).

Presentation Patterns and Key History

— Insomnia and frequent nocturnal awakenings dominate over hypersomnolence

— Awakening with dyspnea or air hunger (especially Cheyne-Stokes)

— Witnessed apneas described as "stops breathing without snoring or struggling"

— Cardiac: HF symptoms (orthopnea, PND, edema, exercise tolerance), prior MI, AF, recent ejection fraction

— Neurologic: Prior stroke (especially brainstem/medullary), Chiari malformation, Parkinson disease, multiple system atrophy

— Renal: ESRD on dialysis (CSA prevalence ~50%; metabolic alkalosis lowers apneic threshold)

— Medications: Chronic opioids (morphine equivalents, methadone dose), benzodiazepines, gabapentinoids, baclofen

— Altitude exposure: Recent travel >2500 m, mountaineering

— OSA treatment history: Recent CPAP initiation with persistent or worsening events

— Epworth Sleepiness Scale often lower than in OSA (5–10 range)

— STOP-BANG less sensitive — designed for OSA

— Use Insomnia Severity Index alongside

— "Wife reports he stops breathing, then breathes faster and deeper, then stops again"

— "Started CPAP 6 weeks ago for OSA; now feels worse, more awakenings"

— "Methadone maintenance, dose 120 mg daily, partner notes nighttime pauses"

Step 3 management: When a HF patient reports these symptoms, first optimize HF therapy (titrate ACEi/ARNI, beta-blocker, MRA, SGLT2i, diuretics) before ordering polysomnography — many CSA events resolve with euvolemia. Re-evaluate sleep symptoms after 4–6 weeks of guideline-directed optimization, then refer to sleep medicine if persistent.

Symptom triad differs from OSA:

Compared to OSA: Less loud snoring, less obesity dependence, less morning headache from hypercapnia (most CSA is hypocapnic/eucapnic, except opioid-induced and hypoventilation syndromes which are hypercapnic).

Targeted history — ask about:

Sleep questionnaires:

Red-flag history phrases on stems:

Physical Exam Findings and Hemodynamic Assessment

— CSA patients are often NOT obese (unlike OSA) — normal or low BMI common

— Look for cachexia in advanced HF or malignancy-related opioid use

— Mallampati and neck circumference usually unremarkable

— S3 gallop, displaced PMI, elevated JVP, bibasilar crackles, lower extremity edema → suggests HFrEF-driven Cheyne-Stokes

— Irregularly irregular pulse → AF, often coexists

— Narrow pulse pressure, cool extremities → low output state

— Generally clear unless concurrent COPD or HF

— Watch for kyphoscoliosis or neuromuscular weakness suggesting hypoventilation (a CSA variant)

— Cranial nerve deficits, ataxia → brainstem stroke or Chiari (obtain MRI)

— Autonomic dysfunction (orthostasis, anhidrosis) → multiple system atrophy

— Bulbar weakness, fasciculations → ALS-related central hypoventilation

— Crescendo-decrescendo waxing/waning with apneic pauses 10–40 seconds → Cheyne-Stokes

— Slow, shallow, regular breathing with apneas → opioid-induced (ataxic "Biot" pattern classic for opioids)

— Irregular gasping → brainstem injury

— Resting hypocapnia (PaCO₂ <38 mmHg) on ABG strongly predicts hypocapnic CSA

— Elevated NT-proBNP correlates with CSA severity in HF

— Pulmonary hypertension on echo raises concern for CSA contributing to right heart strain

Key distinction: Cheyne-Stokes = smooth crescendo-decrescendo, long cycle (~60 sec), seen in HF and stroke. Biot/ataxic = irregular amplitude and timing, no crescendo, classic for opioid-induced CSA. Recognizing the pattern on a stem image or telemetry strip is a high-yield Step 3 visual cue that points toward etiology before polysomnography is even ordered.

General appearance:

Cardiovascular exam (most diagnostically useful):

Pulmonary exam:

Neurologic exam:

Observed breathing pattern in clinic or on telemetry:

Hemodynamic correlates:

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— BMP/CMP: Bicarbonate to assess chronic CO₂ retention vs. metabolic alkalosis (dialysis-related CSA)

— TSH: Hypothyroidism can blunt ventilatory drive and mimic central events

— CBC: Polycythemia (Hct >52% men, >48% women) suggests chronic hypoxemia — more typical of hypoventilation/OSA but supportive

— NT-proBNP or BNP: Elevated supports HF-driven Cheyne-Stokes

— HbA1c, lipid panel: Cardiometabolic risk co-management

— Indication: suspected hypoventilation, neuromuscular disease, severe obesity, daytime hypercapnia

— Hypocapnic CSA (PaCO₂ <38): HF, idiopathic, high-altitude, post-stroke

— Hypercapnic CSA (PaCO₂ >45): opioids, obesity hypoventilation, neuromuscular disease, central hypoventilation syndromes

— Look for AF, prior MI (Q waves), LVH, conduction disease

— Nocturnal bradyarrhythmias on ambulatory monitoring suggest apnea-related vagal surges

— Transthoracic echocardiogram: Mandatory if HF suspected — quantifies LVEF, RV function, PASP

— Chest X-ray: Cardiomegaly, pulmonary congestion, kyphoscoliosis

— Brain MRI: If focal neuro signs, new-onset CSA without HF/opioids, suspected Chiari or brainstem lesion

— Calculate total morphine milligram equivalents (MME); MME ≥200/day strongly associated with CSA

— Review benzos, baclofen, gabapentin/pregabalin — all can suppress ventilatory drive

Board pearl: A non-obese patient with new CSA, no HF on echo, and no opioid use → order brain MRI to evaluate for brainstem stroke, Chiari I malformation, or posterior fossa mass. "Idiopathic CSA" is a diagnosis of exclusion only after structural and pharmacologic causes are ruled out.

First-tier outpatient labs:

Arterial blood gas (selected patients):

ECG:

Imaging:

Medication reconciliation:

Diagnostic Workup — Confirmatory Polysomnography

— CAHI ≥5/hr with >50% of total events being central

— Central event = ≥10-second pause in airflow with absent respiratory effort on thoracic and abdominal belts

— Distinguishes from obstructive events, which show continued effort against a closed airway

— ≥3 consecutive central apneas/hypopneas with crescendo-decrescendo tidal volume, cycle length ≥40 sec, OR

— ≥5 central events/hr with the crescendo-decrescendo pattern over ≥2 hr of monitoring

— Predominant obstructive events on diagnostic study → switch to predominantly central events (CAHI ≥5 and >50% central) after PAP initiation

— Often resolves spontaneously over 2–3 months with continued CPAP

— Split-night acceptable if diagnostic portion confirms severe disease and titration time adequate

— Full-night preferred in HF patients or when Cheyne-Stokes suspected

— Transcutaneous CO₂ (TcCO₂) helps identify hypoventilation phenotype

— End-tidal CO₂ less reliable in supine sleep

— After major HF therapy optimization

— After opioid taper

— After 2–3 months of CPAP for complex CSA (assess resolution)

Step 3 management: Always order in-lab PSG, not HSAT, when CSA is suspected. If a stem gives you a HF patient with a negative HSAT but persistent symptoms, the next step is in-lab PSG — HSAT false-negatives for central events are a classic Step 3 trap.

In-laboratory polysomnography (PSG) is the gold standard for CSA. Home sleep apnea tests (HSAT) are inadequate because they often cannot reliably distinguish central from obstructive events (limited effort channels) and miss Cheyne-Stokes scoring.

PSG diagnostic criteria for CSA:

Cheyne-Stokes scoring:

Treatment-emergent (complex) CSA:

Split-night vs. full-night studies:

Additional channels worth noting:

Repeat testing indications:

Risk Stratification and First-Line Management Logic

— HF-related Cheyne-Stokes: Optimize GDMT — ACEi/ARNI, beta-blocker, MRA, SGLT2i, diuretics; cardiac resynchronization if indicated (QRS ≥150, LBBB, EF ≤35%)

— Opioid-induced: Taper or rotate opioid; reduce MME; discontinue concurrent benzodiazepines

— High-altitude: Descend or acclimatize; acetazolamide 250–500 mg at bedtime

— Stroke-related: Often improves spontaneously over weeks to months

— Dialysis-related: Adjust dialysate bicarbonate, consider nocturnal hemodialysis

— CPAP is first-line for most persistent CSA, including HF-related Cheyne-Stokes (CANPAP trial: no mortality benefit but improved AHI, EF, and 6MWT in responders)

— Adaptive servo-ventilation (ASV) if CPAP fails AND LVEF >45% (contraindicated if LVEF ≤45% per SERVE-HF)

— Bilevel PAP with backup rate (BPAP-ST) for hypercapnic CSA (opioid-induced, neuromuscular)

— Supplemental O₂ at 2–4 L/min nocturnally — useful adjunct in HF-CSA, reduces CAHI by raising apneic threshold

— Phrenic nerve stimulation (remedē System) — implantable device for moderate-severe CSA refractory to PAP

— LVEF, NT-proBNP, baseline CAHI, oxygen desaturation index, daytime PaCO₂

Board pearl: The SERVE-HF trial showed increased cardiovascular mortality with ASV in patients with HFrEF (LVEF ≤45%) and predominant CSA. ASV is contraindicated in this group. This is one of the most frequently tested pieces of evidence-based sleep medicine on Step 3.

Step 1 — Identify and treat the underlying cause (this is the cornerstone of CSA management and the most-tested concept):

Step 2 — Reassess after 4–8 weeks of treating the cause; many CSA cases resolve.

Step 3 — Device therapy if CSA persists:

Risk stratification factors:

Pharmacotherapy — First-Line and Adjunct Agents

— Dose: 250–500 mg PO at bedtime (HF-CSA, idiopathic CSA, high-altitude)

— Mechanism: Induces mild metabolic acidosis → raises baseline PaCO₂ above the apneic threshold → stabilizes breathing

— Best evidence: High-altitude periodic breathing (prophylaxis and treatment); modest benefit in HF-CSA

— Side effects: Paresthesias, metallic taste, polyuria, kidney stones, hypokalemia, metabolic acidosis

— Contraindications: Sulfa allergy (relative), severe CKD (eGFR <30), hepatic cirrhosis (precipitates encephalopathy)

— 2–4 L/min via nasal cannula

— Reduces CAHI in HF-CSA by ~50% in responders; consider when PAP not tolerated

— Does NOT improve mortality but improves symptoms and oxygenation

— Respiratory stimulant; rarely used due to narrow therapeutic index and arrhythmogenicity in HF

— Avoid in AF, ischemic heart disease

— Taper to lowest effective dose; rotate to buprenorphine (ceiling effect on respiratory depression) when feasible

— Discontinue concurrent benzodiazepines, gabapentinoids

— Naloxone has no role in chronic CSA (only acute overdose)

— Sacubitril-valsartan, SGLT2 inhibitors, MRAs all reduce CAHI indirectly by improving cardiac function and reducing pulmonary congestion

Step 3 management: For a patient ascending to high altitude with prior CSA or known periodic breathing, prescribe acetazolamide 125–250 mg BID starting 24 hours before ascent, continue for 48 hours at altitude. Counsel on paresthesias and adequate hydration.

Pharmacology in CSA is limited and largely adjunctive — device therapy and treating the underlying cause remain primary. But these agents are testable:

Acetazolamide (carbonic anhydrase inhibitor):

Supplemental nocturnal oxygen:

Theophylline:

Buspirone, mirtazapine, SSRIs: Investigational; not standard of care

Opioid management (cause-directed pharmacotherapy):

HF GDMT as CSA therapy:

Device Therapy and Procedural Management

— First-line device for most persistent CSA

— Improves oxygenation, reduces sympathetic tone, may improve LVEF in HF-CSA responders

— Responder defined as ≥50% reduction in CAHI on titration; non-responders need alternative

— Algorithm delivers variable pressure support to counter the crescendo-decrescendo pattern

— Indication: Persistent CSA on CPAP AND LVEF >45%, or treatment-emergent CSA, or idiopathic CSA

— Contraindication: LVEF ≤45% with predominant CSA (SERVE-HF — 2.5% absolute increase in CV mortality)

— Also useful in opioid-induced CSA when taper not feasible

— Preferred for hypercapnic CSA (opioid-related, obesity hypoventilation overlap, neuromuscular disease, central hypoventilation syndromes)

— Provides assured ventilation when patient fails to trigger breaths

— Transvenous implantable device, stimulates phrenic nerve to produce regular diaphragm contraction during sleep

— FDA-approved for moderate-severe CSA in adults

— Reasonable in PAP-intolerant patients, including those with HFrEF (does not have ASV mortality signal)

— Implanted by EP/cardiology; lead in left pericardiophrenic or right brachiocephalic vein

— Cardiac resynchronization therapy in eligible HFrEF patients

— Heart transplantation often resolves Cheyne-Stokes entirely

— AF ablation may reduce CSA burden

CCS pearl: For an inpatient with newly diagnosed HFrEF and Cheyne-Stokes on telemetry: order echo, BNP, sleep medicine consult, optimize diuresis and initiate GDMT (ARNI, beta-blocker, MRA, SGLT2i), and arrange outpatient PSG after compensation. Do not order ASV during admission if LVEF ≤45%.

CPAP (continuous positive airway pressure):

Adaptive servo-ventilation (ASV):

Bilevel PAP with backup rate (BPAP-ST):

Supplemental oxygen: As above; second-line or adjunct

Phrenic nerve stimulation (remedē System):

Cardiac procedures that reduce CSA:

Special Populations — Elderly and Renal/Hepatic Impairment

— CSA prevalence rises sharply: up to 20% of community-dwelling elderly have CAHI ≥5

— Often coexists with OSA (mixed apnea); polypharmacy and HF prevalence increase risk

— Cognitive impact: Untreated CSA contributes to executive dysfunction and may worsen dementia trajectory

— Acetazolamide dosing: start low (125 mg), monitor for falls, electrolyte disturbance, dehydration

— PAP adherence challenges: arthritis, claustrophobia, caregiver setup needed — consider nasal pillows, ramp features, and involve family in equipment training

— Avoid sedative-hypnotics (zolpidem, benzodiazepines) that worsen central events and increase fall risk

— ESRD on hemodialysis: CSA prevalence 30–50%; mechanism includes metabolic alkalosis (high dialysate bicarbonate), fluid shifts, uremic toxin effects on ventilatory control

— Strategies: lower dialysate bicarbonate (within tolerable range), nocturnal or more frequent dialysis, optimize volume status

— Acetazolamide avoid if eGFR <30 (risk of severe metabolic acidosis, accumulation)

— Renal transplantation may reduce CSA burden

— Cirrhosis with hepatic encephalopathy can produce central apneas and irregular breathing

— Hepatopulmonary syndrome causes hypoxemia but not CSA per se

— Acetazolamide contraindicated in advanced cirrhosis — risk of precipitating encephalopathy and worsening acidosis

— Avoid opioids; if needed, use lowest dose with cautious titration; benzodiazepines worsen both encephalopathy and ventilatory control

Key distinction: In an ESRD dialysis patient with new CSA, the mechanism is often metabolic alkalosis from high-bicarbonate dialysate lowering the apneic threshold. The intervention is nephrology-coordinated adjustment of dialysate composition and dialysis schedule, not immediate device escalation — a common Step 3 systems-of-care vignette.

Elderly (≥65 years):

Renal impairment:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— CSA is uncommon in pregnancy; OSA is the dominant sleep-disordered breathing concern (weight gain, upper airway edema)

— If CSA suspected, evaluate for cardiomyopathy (peripartum cardiomyopathy), hyperthyroidism, opioid use

— Acetazolamide is Category C — avoid in first trimester; limited safety data; use only if benefit clearly outweighs risk (e.g., refractory idiopathic intracranial hypertension)

— PAP therapy is safe in pregnancy; titrate pressures as gestation progresses (weight gain may require uptitration)

— Congenital central hypoventilation syndrome (CCHS, "Ondine's curse"): PHOX2B gene mutation; presents in neonates with hypoventilation when asleep, normal breathing when awake

— Requires lifelong nocturnal ventilatory support (BPAP-ST, tracheostomy with ventilator, or diaphragm pacing)

— Associated with Hirschsprung disease and neural crest tumors (neuroblastoma) — screen accordingly

— Arnold-Chiari malformation: pediatric CSA may be presenting feature; MRI brain mandatory

— Prader-Willi syndrome: mixed central and obstructive events; cautious growth hormone therapy

— CSA peaks in first 3 months post-stroke, often improves spontaneously

— Treatment improves daytime alertness and may aid rehabilitation

— Acclimatized residents at >2500 m have higher baseline CAHI; usually asymptomatic

— Travelers should consider acetazolamide prophylaxis

— Methadone has higher CSA risk than buprenorphine

— Do not discontinue MAT abruptly; coordinate with addiction medicine

Board pearl: A neonate with cyanotic episodes during sleep, normal breathing when awake, and constipation since birth → suspect CCHS with associated Hirschsprung disease. Order PHOX2B genetic testing and rectal suction biopsy; arrange chronic nocturnal ventilatory support.

Pregnancy:

Pediatrics:

Post-stroke patients:

Athletes and high-altitude residents:

Opioid use disorder patients on methadone/buprenorphine maintenance:

Complications and Adverse Outcomes

— Increased sympathetic tone → hypertension, especially nocturnal non-dipping pattern

— Worsening HF: CSA accelerates LV remodeling, increases hospitalizations

— Atrial fibrillation: Bidirectional relationship — CSA promotes AF, AF worsens CSA

— Ventricular arrhythmias and sudden cardiac death risk elevated, especially in HFrEF + Cheyne-Stokes

— Stroke risk increased independent of HF

— Chronic nocturnal hypoxemia → pulmonary vasoconstriction → group 3 PH overlap

— Right heart failure in severe untreated disease

— Sleep fragmentation → impaired attention, memory, executive function

— Increased motor vehicle crash risk (though less than OSA)

— Depression and anxiety frequently comorbid

— Insomnia, fatigue, reduced exercise tolerance

— Bed partner sleep disruption

— HF-CSA independently associated with increased all-cause mortality (HR ~1.5–2.0)

— Severity (CAHI), oxygen desaturation burden, and Cheyne-Stokes pattern all predict worse outcomes

— ASV in HFrEF ≤45%: Excess CV mortality (SERVE-HF)

— CPAP intolerance: mask leaks, claustrophobia, aerophagia

— Acetazolamide: metabolic acidosis, electrolyte disturbance, nephrolithiasis, paresthesias

— Oxygen therapy: rare CO₂ retention in hypercapnic phenotypes — monitor ABG

Key distinction: Untreated OSA carries well-established mortality risk reducible by CPAP. Untreated CSA carries comparable cardiovascular risk, but PAP therapy has not reliably reduced mortality in trials (CANPAP, SERVE-HF). Treatment goals focus on symptoms, sleep quality, and underlying disease control, not survival per se — a nuanced Step 3 evidence-based concept.

Cardiovascular complications (dominant morbidity):

Pulmonary hypertension:

Neurocognitive:

Quality of life:

Mortality:

Treatment-related complications:

Falls and injuries: From daytime sleepiness and nocturnal arousals, particularly in elderly

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Suspected CSA on clinical grounds with HF, opioids, stroke, or neuromuscular disease

— Treatment-emergent CSA on CPAP not resolving by 2–3 months

— Failed PAP therapy or intolerance

— Need for advanced device titration (ASV, BPAP-ST, phrenic stimulator candidacy)

— New Cheyne-Stokes with reduced EF — coordinate GDMT optimization and CRT/ICD candidacy

— Phrenic nerve stimulator implantation

— Refractory AF possibly driven by CSA

— New CSA without HF/opioid cause — evaluate for brainstem lesion, Chiari, MSA, ALS

— Post-stroke CSA persisting beyond 3 months

— Hypercapnic CSA with daytime PaCO₂ >50 — initiate NIV, assess for chronic ventilatory support

— Concurrent COPD, neuromuscular disease, or obesity hypoventilation overlap

— Acute decompensated HF with severe Cheyne-Stokes and hypoxemia

— Opioid overdose or severe respiratory depression

— Acute hypercapnic respiratory failure (pH <7.30, PaCO₂ >55) — requires NIV or intubation

— New brainstem stroke with abnormal breathing pattern

— Respiratory failure requiring intubation or continuous NIV monitoring

— Hemodynamic instability with severe nocturnal arrhythmias

— Post-cardiac arrest evaluation

— Ensure PAP equipment ordered, fitting completed, follow-up scheduled before discharge

— Communicate apnea diagnosis to PCP and cardiology in discharge summary

CCS pearl: A patient admitted with decompensated HFrEF, witnessed Cheyne-Stokes, and SpO₂ nadirs of 82% overnight: orders should include continuous pulse oximetry, telemetry, IV diuresis, GDMT initiation/titration, sleep medicine consult for inpatient or outpatient PSG, supplemental O₂ to keep SpO₂ ≥90%, and defer ASV until LVEF reassessed after optimization.

Indications for sleep medicine consult (outpatient):

Cardiology consult:

Neurology consult:

Pulmonary/critical care consult:

Indications for inpatient admission:

ICU triage criteria:

Transitions of care:

Key Differentials — Same-Category (Sleep-Disordered Breathing) Causes

— Snoring, obesity, witnessed apneas with effort against closed airway

— STOP-BANG ≥3, Mallampati III–IV, neck circumference >17 in (men)

— PSG: events show continued thoracoabdominal effort

— Coexistence common: "Mixed apnea" patient may need both anti-OSA (CPAP) and CSA strategies

— Predominantly obstructive events on diagnostic PSG → emerging central events on PAP titration

— Often resolves with 8–12 weeks of continued CPAP

— If persistent: switch to ASV (if LVEF >45%) or BPAP-ST

— Subtype of CSA defined by crescendo-decrescendo pattern with cycle length ≥40 sec

— Strongly associated with HFrEF, less commonly with stroke or advanced renal failure

— Ataxic (Biot) breathing pattern, irregular amplitude

— Often hypercapnic — distinguishes from hypocapnic HF-CSA

— Mu-receptor suppression of pre-Bötzinger complex respiratory rhythm

— Hypoxic ventilatory response → hyperventilation → hypocapnia → apnea cycle

— Resolves with descent or acetazolamide

— Diagnosis of exclusion; hypocapnic, no identifiable cause

— Often middle-aged men with insomnia

— CCHS (PHOX2B), late-onset central hypoventilation, ROHHAD syndrome

— Hypercapnic phenotype

— BMI ≥30, daytime PaCO₂ ≥45, no other cause

— Often overlaps with OSA; pure CSA component less common

Key distinction: OSA shows respiratory effort during events (belts continue moving); CSA shows absent effort (belts flat). This single PSG finding is the linchpin of differentiation and the most testable nuance on Step 3 sleep medicine questions.

Obstructive sleep apnea (OSA):

Treatment-emergent (complex) sleep apnea:

Cheyne-Stokes respiration:

Opioid-induced CSA:

High-altitude periodic breathing:

Idiopathic CSA:

Central hypoventilation syndromes:

Obesity hypoventilation syndrome (OHS):

Key Differentials — Other-Category Causes of Nocturnal Symptoms

— Paroxysmal nocturnal dyspnea (PND) from HF: Awakening with dyspnea, but breathing pattern is sustained tachypnea, not periodic apneas

— Nocturnal angina: Chest discomfort awakening patient; ECG and stress testing differentiate

— Arrhythmia-related awakenings: PSVT, AF with RVR — ambulatory monitoring

— COPD/asthma nocturnal worsening: Wheezing, prolonged expiration, hypercapnia; PFTs and clinical exam differentiate

— Pulmonary embolism: Acute dyspnea, pleuritic pain, tachycardia — different tempo

— Interstitial lung disease: Progressive exertional dyspnea, crackles, restrictive PFTs

— Nocturnal seizures: Stereotyped movements, post-ictal confusion; video EEG

— REM sleep behavior disorder: Dream enactment, not apnea

— Periodic limb movement disorder: Leg movements with arousals, no apnea

— Panic attacks at sleep onset: Acute dyspnea, tachycardia, fear — episodic, not periodic

— Anxiety-driven insomnia: No witnessed apneas

— Hypothyroidism: Fatigue, weight gain, can cause mild CSA via blunted drive — TSH screening

— Acromegaly: Macroglossia → OSA more than CSA

— Nocturnal reflux causing cough and awakening; pH probe or empiric PPI

— Alcohol worsens both OSA and CSA; cocaine causes nocturnal sympathetic surges

Board pearl: A patient with HF, awakening with dyspnea and a witnessed pattern that is continuous tachypnea relieved by sitting up has PND, not Cheyne-Stokes. Cheyne-Stokes shows periodic apneas with crescendo-decrescendo breathing, not sustained dyspnea. Distinguishing these on history is a high-yield Step 3 trap.

Cardiac causes mimicking CSA symptoms:

Pulmonary causes:

Neurologic mimics:

Psychiatric:

Endocrine:

GERD:

Substance use:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— ARNI (sacubitril-valsartan) or ACEi/ARB if ARNI contraindicated

— Evidence-based beta-blocker: carvedilol, metoprolol succinate, or bisoprolol

— MRA: spironolactone or eplerenone if K⁺ <5.0 and eGFR >30

— SGLT2 inhibitor: dapagliflozin or empagliflozin (HFrEF and HFpEF)

— Loop diuretic at lowest effective dose

— Anticoagulation if AF (DOAC preferred unless valvular AF or mechanical valve)

— Statin per ASCVD risk

— Document MME on discharge

— Schedule taper plan with PCP or pain specialist

— Consider buprenorphine rotation

— Co-prescribe naloxone if MME ≥50/day or any concurrent benzodiazepine

— Counsel against alcohol and sedative use

— Ensure PAP machine delivered, mask fitted before discharge when feasible

— Educate on minimum 4 hr/night use (Medicare adherence threshold: ≥4 hr on 70% of nights over 30-day window in initial 90 days)

— Schedule download review at 30 and 90 days

— Weight loss (if applicable)

— Limit alcohol within 3 hr of bedtime

— Avoid supine sleep if positional component

— Sodium and fluid restriction in HF

— Annual influenza, pneumococcal series, COVID-19 boosters, RSV (age ≥60), Tdap

Step 3 management: At discharge, co-prescribe naloxone for any patient with opioid-induced CSA who is continuing opioid therapy, particularly if MME ≥50/day. This is an evidence-based safety intervention emphasized by CDC and USPSTF guidance and frequently tested as a patient safety action item.

Discharge medication checklist for CSA-associated HF admission:

Opioid stewardship (for opioid-induced CSA):

Device adherence plan:

Lifestyle and risk factor modification:

Vaccinations:

Follow-Up, Monitoring Parameters, and Counseling

— 2–4 weeks post-PAP initiation: Phone or in-person check on adherence, mask comfort, symptom response

— 30 days: First device data download — review usage hours, residual AHI, leak; troubleshoot

— 90 days: Insurance/Medicare adherence review (≥4 hr on 70% of nights required for continued coverage)

— 6 months and annually thereafter: Symptom reassessment, device download, mask replacement schedule

— Repeat PSG if symptoms recur, after major clinical change (HF decompensation, opioid taper, weight change >10%), or after 2–3 months of CPAP for complex CSA to verify resolution

— Epworth Sleepiness Scale and Insomnia Severity Index at each visit

— Residual AHI on device (goal <5/hr)

— SpO₂ nocturnal nadir if recurrent symptoms

— BNP/NT-proBNP and echo per HF protocol

— Electrolytes and bicarbonate if on acetazolamide (baseline, 2 weeks, then quarterly)

— Driving safety: Counsel against driving when sleepy; some states require reporting of sleep apnea for commercial drivers — know your state law

— Travel: PAP machines allowed on aircraft, battery backup recommended; humidifier optional

— Surgery/anesthesia: Notify anesthesiologists pre-op; bring own PAP; opioid-sparing strategies

— Bed partner education: Recognize warning signs of decompensation (resumption of witnessed apneas, weight gain, edema)

— Useful adjunct in HF and overlap with COPD

— Improves exercise tolerance and quality of life

Board pearl: Medicare PAP coverage criteria require ≥4 hr nightly use on ≥70% of nights during a consecutive 30-day window within the first 90 days. Failure to meet this benchmark results in equipment recall. Document adherence clearly and intervene early on barriers — a Step 3 health systems pearl.

Follow-up schedule:

Monitoring parameters:

Counseling points:

Pulmonary rehabilitation:

Ethical, Legal, and Patient Safety Considerations

— Commercial drivers (CDL holders): FMCSA recommends screening and treatment for sleep apnea; uncontrolled disease may disqualify from CDL certification

— Many states require physician reporting of conditions impairing driving safety — know your state's mandatory reporting law (e.g., California requires reporting of "disorders characterized by lapses of consciousness")

— Document counseling against driving while sleepy

— ASV in HFrEF: Must explicitly disclose the SERVE-HF mortality signal if considering ASV in any patient with LVEF ≤45%, even off-label; preferred to avoid entirely

— Phrenic nerve stimulator implantation: Invasive procedure — discuss alternatives, infection and lead-displacement risks

— Co-prescribe naloxone for high-risk patients (MME ≥50/day, concurrent benzodiazepines, history of overdose)

— Check state PDMP (prescription drug monitoring program) before each opioid prescription

— Avoid concurrent benzodiazepines whenever possible

— Document risk-benefit discussion for chronic opioid therapy

— Hospital discharge without PAP equipment in place is a frequent failure point — confirm DME order, delivery date, and follow-up before discharge

— Communicate sleep diagnosis to all downstream providers; CSA changes perioperative risk

— Sleep apnea increases risk of postoperative respiratory failure

— Use multimodal opioid-sparing analgesia; continuous pulse oximetry post-op for moderate-severe disease

— PAP adherence lower in low-income and minority populations — address access, education, language barriers

— In advanced HF with severe Cheyne-Stokes, discuss goals of care; CSA may be a marker of poor prognosis

Step 3 management: A commercial truck driver newly diagnosed with severe CSA and excessive daytime sleepiness should be counseled not to drive commercially until treated and adherent, with documentation in the chart. Coordinate with employer's medical examiner per FMCSA guidance — a classic Step 3 patient safety and occupational medicine intersection.

Driving and occupational safety:

Informed consent edge cases:

Opioid prescribing safety:

Transitions of care risks:

Perioperative safety:

Health equity:

Advance care planning:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When in doubt on a Step 3 CSA question, first treat the underlying cause (optimize HF therapy, taper opioids, descend from altitude), then reassess, and only then escalate to device therapy — and never choose ASV when LVEF ≤45%. These three rules answer the majority of CSA vignettes.

HFrEF + Cheyne-Stokes → CPAP first; avoid ASV if LVEF ≤45% (SERVE-HF)

Chronic methadone >200 MME/day → ataxic (Biot) breathing → hypercapnic CSA → BPAP-ST and opioid taper

High altitude >2500 m → periodic breathing → acetazolamide 125–250 mg BID prophylaxis

PHOX2B mutation → Congenital central hypoventilation syndrome (Ondine's curse) + Hirschsprung + neuroblastoma risk

Arnold-Chiari malformation → CSA in children and young adults → MRI brain → neurosurgical decompression

ESRD on hemodialysis → CSA from high-bicarbonate dialysate → adjust dialysate, nocturnal HD

New CSA + brainstem signs → MRI brain for stroke or posterior fossa lesion

Post-stroke CSA → usually improves in 3 months

AF + HFrEF + Cheyne-Stokes → bidirectional relationship; rhythm control + CSA treatment both help

Treatment-emergent CSA → often resolves with continued CPAP over 2–3 months

PSG hallmark of central event → ≥10 sec airflow cessation without thoracoabdominal effort

Cheyne-Stokes cycle length → ≥40 seconds, crescendo-decrescendo pattern

Hypocapnic CSA (PaCO₂ <38) → HF, idiopathic, altitude, post-stroke

Hypercapnic CSA (PaCO₂ >45) → opioids, neuromuscular disease, OHS overlap

Phrenic nerve stimulator (remedē) → safe alternative in HFrEF where ASV contraindicated

Acetazolamide contraindications → sulfa allergy (relative), eGFR <30, cirrhosis

Medicare PAP adherence → ≥4 hr on ≥70% of nights in 30-day window during first 90 days

Naloxone co-prescription threshold → opioid MME ≥50/day or concurrent benzodiazepine

Buprenorphine preferred over methadone in opioid maintenance for sleep apnea risk

Nocturnal O₂ at 2–4 L/min → useful adjunct in HF-CSA, no mortality benefit

Board Question Stem Patterns

— 68-year-old man with HFrEF (EF 30%) on optimized GDMT, witnessed crescendo-decrescendo breathing with pauses, ESS 12. PSG: CAHI 25/hr, >50% central, Cheyne-Stokes pattern.

— Best answer: CPAP titration (not ASV — LVEF ≤45%); supplemental O₂ if intolerant

— Trap answer: Adaptive servo-ventilation

— 55-year-old on methadone 150 mg daily and clonazepam, partner reports irregular pauses and gasping; ABG shows PaCO₂ 52

— Best answer: Taper benzodiazepine first, reduce/rotate opioid, consider BPAP-ST, co-prescribe naloxone

— Trap: Start ASV immediately

— Patient with severe OSA started on CPAP 6 weeks ago, residual AHI 12 with mostly central events

— Best answer: Continue CPAP for 2–3 months and reassess; most resolve

— Trap: Immediate switch to ASV

— Mountaineer ascending to 4000 m, prior periodic breathing

— Best answer: Acetazolamide 125–250 mg BID starting day before ascent

— Neonate with cyanotic episodes during sleep, constipation, normal awake breathing

— Best answer: PHOX2B testing for CCHS; evaluate for Hirschsprung

— ESRD on HD with new witnessed apneas; PSG shows central events

— Best answer: Adjust dialysate bicarbonate, nephrology coordination; not immediate ASV

— Brainstem stroke 2 weeks ago, new irregular nocturnal breathing

— Best answer: Supportive care, repeat PSG in 3 months — often resolves

— Newly diagnosed severe CSA, CDL holder

— Best answer: Counsel against commercial driving until treated and adherent; document; report per FMCSA/state law

Key distinction: Step 3 stems will often present an answer choice that is correct for OSA but wrong for CSA (e.g., immediate CPAP without addressing HF). The right approach is always cause-directed first, then device therapy — recognizing this hierarchy is the highest-yield strategic skill.

Pattern 1 — The HF Cheyne-Stokes vignette:

Pattern 2 — The opioid-induced CSA vignette:

Pattern 3 — Treatment-emergent CSA:

Pattern 4 — The high-altitude trekker:

Pattern 5 — The pediatric vignette:

Pattern 6 — The dialysis patient:

Pattern 7 — The post-stroke patient:

Pattern 8 — The commercial driver:

One-Line Recap

Central sleep apnea is a heterogeneous disorder defined by repetitive cessation of airflow without respiratory effort — the cornerstone of management is identifying and treating the underlying cause (HF, opioids, stroke, altitude, dialysis, structural brainstem disease) before escalating to device therapy, while remembering that ASV is contraindicated in HFrEF with LVEF ≤45%.

— In-lab polysomnography is required (HSAT inadequate); central event = ≥10 sec airflow cessation without thoracoabdominal effort; CAHI ≥5/hr with >50% central events; Cheyne-Stokes requires crescendo-decrescendo cycles ≥40 seconds.

— Optimize HF GDMT (ARNI, beta-blocker, MRA, SGLT2i); taper opioids and discontinue concurrent benzodiazepines; acetazolamide for altitude and idiopathic hypocapnic CSA; adjust dialysate bicarbonate in ESRD; image the brainstem if no metabolic or cardiac cause.

— CPAP first-line for persistent CSA including HF-Cheyne-Stokes; ASV only if LVEF >45% (SERVE-HF mortality signal); BPAP-ST for hypercapnic phenotypes (opioids, neuromuscular, OHS overlap); supplemental nocturnal O₂ as adjunct; phrenic nerve stimulation (remedē) as PAP-intolerant alternative even in HFrEF.

— Co-prescribe naloxone when opioid MME ≥50/day; ensure Medicare PAP adherence (≥4 hr on ≥70% of nights in 30-day window during first 90 days); counsel commercial drivers and follow state mandatory reporting laws; arrange sleep medicine follow-up at 30 and 90 days with device data download review; reassess with repeat PSG after major clinical change (HF compensation, opioid taper, weight shift).

Board pearl: The single most-tested rule in Step 3 central sleep apnea: treat the cause first, choose CPAP over ASV when LVEF ≤45%, and never overlook opioid stewardship and naloxone co-prescription as part of the management plan.

Diagnostic anchor:

Cause-first treatment algorithm:

Device therapy hierarchy:

Step 3 systems and safety pearls: